Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Positron Emission Tomography scan · 1 trial · 5 indications
| Name | Type | Description |
|---|---|---|
| Positron Emission Tomography (PET) scan | PROCEDURE | - |
Inclusion Criteria: * Male or female. (If female of child-bearing potential and outside of the window of 10 days since the last menstrual period, a negative serum or urine pregnancy test is required.) * Known or suspected primary or metastatic tumours * Age equal to or greater than 15 years * Able ...
Positron Emission Tomography scan is an investigational imaging agent being studied for use in patients with brain neoplasms, as well as lung, thyroid, and colorectal neoplasms and lymphoma. It is being evaluated as a diagnostic tool to detect cancer or suspected cancer in these patient populations.
Positron Emission Tomography scan is being developed by Avalon GloboCare Corp., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ALBT. The company is conducting clinical research to evaluate the imaging agent's potential in oncology applications.
Positron Emission Tomography scan is in Phase 2 clinical development. It is an investigational agent and has not been approved by regulatory authorities. The Phase 2 trial has been completed, and the agent remains under clinical investigation for its intended oncology indications.
Positron Emission Tomography scan has one completed clinical trial, NCT00123760, titled 'Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer.' This Phase 2 study enrolled 10,838 participants in Canada and evaluated the agent across multiple cancer types, including brain neoplasms.
Yes, Positron Emission Tomography scan is also known as FluGlucoScan, which is the name used in the clinical trial NCT00123760. The trial evaluated 18F-Fluorodeoxyglucose (FluGlucoScan) in patients with cancer or suspected cancer, including those with brain neoplasms.